Y-mAbs Therapeutics Inc (YMAB) Short-Term Debt to Equity
Y-mAbs Therapeutics (YMAB) management demonstrates high professionalism in controlling R&D costs and ensuring transparency across all stages of antibody implementation. The daily price action, where the indicator stands at 0.01, illustrates the business potential for delivering exclusive therapies to global medical centers with high profitability. The brand's strong authority in pediatric oncology and the trust of specialists confirm the ethical significance of the company's activities.
%3A%20Short-Term%20Debt%20to%20Capital%20Ratio&width=1200&height=400&colorIndex=0&v=mvvwvvs9.gq-7b28iyo&start=20220704&end=20261031&filename=GURU_Markets_-_YMAB_-_Y-mAbs-Therapeutics_-_Short-Term-Debt-to-Capital-Ratio "YmAbs - YMAB Short-Term Debt to Capital (period 07/04/2022 - 09/27/2025) | 👁️GURU.Markets👁️")
Financial and market metric breakdowns for ymabs.com (YMAB)
Finding a fundamental balance between asset cost and quality requires an analysis of resilience to credit risks. This indicator measures the share of short-term liabilities within the capital structure, determining the business's margin of safety in the event of refinancing difficulties. For Y-mAbs Therapeutics (YMAB), with its monopoly position in pediatric oncology, such a metric confirms financial autonomy against the backdrop of inelastic demand for Danyelza. The historical trend of short-term loans to equity visualizes the current level of debt load.